13F HOLDINGS REPORT
Sanofi
Quarter ended Q2 2025 · Filed July 29, 2025 · Accession 0000950123-25-006717
Total Value
$175.7M
Positions
10
Other Managers
0
Confidential Omitted
No
Holdings (10)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | MeiraGTx Holdings plc | MGTX | 12,197,737 | $79.5M | 45.25% |
| 2 | Novavax | NVAX | 6,880,481 | $43.3M | 24.67% |
| 3 | AnaptysBio | ANABV | 821,917 | $18.2M | 10.38% |
| 4 | Inhibrx Biosciences, Inc. | INBX | 1,157,926 | $16.5M | 9.40% |
| 5 | Omada Health Inc. | OMDA | 524,903 | $9.6M | 5.47% |
| 6 | LAVA Therapeutics N.V. | N51517105 | 1,919,455 | $2.5M | 1.44% |
| 7 | Eledon | ELDN | 814,980 | $2.2M | 1.26% |
| 8 | Inozyme, Inc | 45790W108 | 443,255 | $1.8M | 1.01% |
| 9 | IGM Biosciences | 449585108 | 1,438,975 | $1.6M | 0.92% |
| 10 | Q32 Bio Inc. | QTTB | 244,083 | $363,684 | 0.21% |